Breaking News

InflaRx Opens New Research Facility

Lead candidate, IFX-1 is advancing through clinical trials with Phase IIB data in hidradenitis suppurativa expected 1H19

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

InflaRx N.V., a German-based biopharma company developing therapeutics to treat life-threatening inflammatory diseases, has opened a new research facility in Ann Arbor, MI. The facility will be part of InflaRx Pharmaceuticals Inc., a wholly owned U.S. subsidiary of the InflaRx N.V. group, and operations will serve to further develop and extend the company’s complement system-based therapeutics. “At InflaRx, our primary focus is to discover and develop complement-based therapeutics that can ch...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters